Business Update31 Dec 2025, 07:21 pm
Bajaj Healthcare Receives CDSCO Approval for Suvorexant Tablets Clinical Trial and Bioequivalence Study
AI Summary
Bajaj Healthcare Ltd has announced that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to conduct a clinical trial and bioequivalence study of Suvorexant Tablets. This approval follows the recommendation received from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of CDSCO for conducting Phase Ill clinical trials for Suvorexant Tablets.
Key Highlights
- Bajaj Healthcare has received approval from CDSCO to conduct clinical trial and bioequivalence study of Suvorexant Tablets.
- The approval is based on the recommendation received from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of CDSCO for conducting Phase Ill clinical trials for Suvorexant Tablets.
- The approval enables the Company to conduct the clinical trial and bioequivalence study of Suvorexant Tablets.
- This is a significant step for the company in its drug development process.